Disc Medicine (NASDAQ:IRON) Price Target Raised to $118.00

Disc Medicine (NASDAQ:IRON) had its price objective lifted by HC Wainwright from $70.00 to $118.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.88) EPS, FY2024 earnings at ($3.88) EPS, Q1 2025 earnings at ($1.02) EPS, Q2 2025 earnings at ($1.17) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($1.50) EPS.

Several other brokerages have also issued reports on IRON. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target for the company. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Wedbush restated an “outperform” rating and set a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a research note on Tuesday. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Buy” and a consensus target price of $85.80.

Disc Medicine Stock Down 2.0 %

Shares of IRON opened at $59.46 on Wednesday. The stock has a market capitalization of $1.77 billion, a P/E ratio of -14.94 and a beta of 0.60. The firm has a fifty day simple moving average of $51.20 and a two-hundred day simple moving average of $44.97. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. Sell-side analysts expect that Disc Medicine will post -4.15 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 7,538 shares of company stock worth $437,875 over the last three months. 4.24% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of IRON. Amalgamated Bank boosted its stake in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine during the second quarter valued at $129,000. Quest Partners LLC purchased a new stake in shares of Disc Medicine during the third quarter valued at $131,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Disc Medicine during the third quarter valued at $146,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.